In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Latest From C.R. Bard

What’s Next? Five Things To Look Out For In August

Second-quarter earnings results from two of the Big Three – Teva and Mylan – hold much of the intrigue in August, while more competition in the nascent Avastin biosimilar market could materialize in Europe.

Sales & Earnings Generic Drugs

Updated: Multiple Biosimilars To Avastin Have Launched In EU

Roche’s biggest seller, Avastin, has fallen to biosimilar competition in Europe, with at least one company confirming launch to Generics Bulletin.

BioPharmaceutical Cancer

Samsung Bioepis Added To Avastin Biosimilar Litigants

Samsung Bioepis is the latest company to stare down a lawsuit from Genentech over Avastin patents in the US. The Korean firm is aiming to be amongst the early biosimilar movers, after the market formed a year ago.

Biosimilars Legal Issues

Nine More Years? Sandoz Loses Again On Enbrel Biosimilar

Sandoz has failed to overturn on appeal an invalidity ruling for two patents covering Enbrel in the US, barring a path to market for its Erelzi biosimilar, potentially until patent expiry in 2029.

Legal Issues Intellectual Property
See All

Company Information

  • Other Names / Subsidiaries
    • Davol, Inc.
    • Embo Medical Limited
    • Liberator Medical, Inc.
    • Lutonix, Inc.
    • Medafor, Inc.
    • Medicon, Inc.
    • Neomend, Inc.
    • Rochester Medical, Inc.
    • Vascular Pathways, Inc.
    • FlowCardia, Inc.
    • Bridger Biomed, Inc.
UsernamePublicRestriction

Register